Q2 2019: Favourable growth continues in Q2
Significant events in the second quarter · Second-quarter net sales amounted to MSEK 180 (153), an increase of 18% (adjusted for currency effects 15%) compared with the second quarter of 2018 · EBITDA for the second quarter amounted to MSEK 57 (43), an increase of 32% compared with the second quarter of 2018 · A successfully completed clinical trial on 326 healthy pregnant women showed that intake of Probi FerroSorb® significantly improved iron status · New product concept launched in the Nordic market, adapted for consumers of all ages, with the products Probi® Baby, Probi®